RecruitingNot ApplicableNCT05579392

A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis

Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis


Sponsor

Rush University Medical Center

Enrollment

30 participants

Start Date

Sep 22, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Crohn's Disease (CD) and Ulcerative Colitis (UC), collectively known as inflammatory bowel disease (IBD), are two of the most significant chronic conditions of the gastrointestinal tract (GIT) and affects over 1.5 million individuals in the U.S. Recently, there has been an increased understanding of the importance of sleep and sleep disruption in IBD as a potentially modifiable risk factor. We, therefore, hypothesize that intervening with morning bright light therapy (BLT) in IBD patients with CM will decrease intestinal permeability and pro-inflammatory cytokines, positively impact intestinal microbiota, and improve quality of life (QoL).


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether bright light therapy — sitting in front of a special bright light box each day — can help people with Crohn's disease or ulcerative colitis by improving gut barrier function and reducing inflammation. It's a crossover trial, meaning participants try both the light therapy and a comparison condition. **You may be eligible if...** - You are 18 or older - You have been diagnosed with Crohn's disease or ulcerative colitis confirmed by biopsy - Your inflammation markers are mildly elevated, or you have fatigue - You have been on a stable dose of your IBD medication (biologic, immunomodulator, or anti-inflammatory) for at least 12 weeks **You may NOT be eligible if...** - Your IBD is currently in a significant flare - You have been diagnosed with major depression or have thoughts of self-harm - You have sleep apnea or restless leg syndrome (based on screening questionnaires) - You regularly take medications that affect gut permeability or melatonin levels (like NSAIDs, beta blockers, or metoclopramide) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEBright Light Therapy

Device: Bright Light Therapy Retimer

DEVICEPlacebo Retimer Device

Device: Placebo Retimer Device with no bright light therapy


Locations(2)

Rush University Medical Center

Chicago, Illinois, United States

Medical University of South Carolina

Charleston, South Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05579392


Related Trials